PATENT PORTFOLIOS AND COMPETITION LAW: SOME REFLECTIONS AFTER THE RECENT RPSA CASES

In the pharmaceutical sector, firms often build patent portfolios in order to better protect their innovations, but also to strategically exploit the cluster to prevent entry by generic competition.In fact, once patent protection on the main invention expires, originator firms adopt a two-tiered strategy, centred on the enforcement of secondary pat

Abstract In the current study, we have systematically analysed the mitochondrial DNA (mtDNA) sequence of Naegleria fowleri (N.fowleri) isolate AY27, isolated from Karachi, Pakistan.The N.fowleri isolate AY27 has a circular mtDNA (49,541 bp), which harbours 69 genes (46 protein-coding genes, welding sweater 21 tRNAs and 2 rRNAs).The pan-genome analy